Ontology highlight
ABSTRACT: Introduction
This phase I/II trial was designed to determine the maximally tolerated dose of thoracic radiotherapy as part of a combined modality approach. This report includes the long-term outcomes of patients treated on this study. The phase II portion was never completed, as RTOG-0617 opened before it was concluded.Methods
In this study, the maximally tolerated dose was defined as 74 Gy of radiation in 37 fractions. Twenty-five patients with unresectable NSCLC were treated with 2-Gy daily fractions and concurrent weekly carboplatin and paclitaxel. Of these patients, 20 had stage III disease and five had stage I or II disease.Results
Patients were followed until death or for a minimum of 5 years in the case of survivors. The median and 5-year survivals were 42.5
SUBMITTER: Schild SE
PROVIDER: S-EPMC5367932 | biostudies-literature | 2017 Apr
REPOSITORIES: biostudies-literature